Systematic Financial Management LP reduced its stake in Myriad Genetics, Inc. (NASDAQ:MYGN) by 18.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,200 shares of the company’s stock after selling 6,890 shares during the quarter. Systematic Financial Management LP’s holdings in Myriad Genetics were worth $1,389,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Acadian Asset Management LLC lifted its position in shares of Myriad Genetics by 2.6% during the third quarter. Acadian Asset Management LLC now owns 2,387,166 shares of the company’s stock valued at $109,812,000 after purchasing an additional 59,446 shares in the last quarter. GHP Investment Advisors Inc. raised its position in Myriad Genetics by 4.5% in the second quarter. GHP Investment Advisors Inc. now owns 53,290 shares of the company’s stock worth $1,991,000 after acquiring an additional 2,305 shares during the period. United Services Automobile Association raised its position in Myriad Genetics by 206.8% in the second quarter. United Services Automobile Association now owns 104,981 shares of the company’s stock worth $1,916,000 after acquiring an additional 70,766 shares during the period. Swiss National Bank raised its position in Myriad Genetics by 2.6% in the second quarter. Swiss National Bank now owns 121,600 shares of the company’s stock worth $4,544,000 after acquiring an additional 3,100 shares during the period. Finally, Wells Fargo & Company MN raised its position in Myriad Genetics by 76.8% in the second quarter. Wells Fargo & Company MN now owns 376,515 shares of the company’s stock worth $14,071,000 after acquiring an additional 163,613 shares during the period. 98.21% of the stock is currently owned by institutional investors and hedge funds.

Several brokerages have commented on MYGN. BidaskClub lowered shares of Myriad Genetics from a “hold” rating to a “sell” rating in a research report on Tuesday, November 13th. TheStreet lowered shares of Myriad Genetics from a “b” rating to a “c” rating in a research report on Thursday, November 8th. ValuEngine downgraded shares of Myriad Genetics from a “buy” rating to a “hold” rating in a research note on Thursday, November 8th. Deutsche Bank lifted their target price on shares of Myriad Genetics from $37.00 to $43.00 and gave the stock a “hold” rating in a research note on Monday, November 5th. Finally, Zacks Investment Research downgraded shares of Myriad Genetics from a “buy” rating to a “hold” rating in a research note on Monday, October 29th. Four analysts have rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $41.90.

MYGN opened at $32.19 on Tuesday. The stock has a market capitalization of $2.35 billion, a PE ratio of 26.83, a price-to-earnings-growth ratio of 1.82 and a beta of 0.51. The company has a debt-to-equity ratio of 0.23, a current ratio of 3.17 and a quick ratio of 2.83. Myriad Genetics, Inc. has a twelve month low of $27.27 and a twelve month high of $50.44.

Myriad Genetics (NASDAQ:MYGN) last posted its earnings results on Tuesday, November 6th. The company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.30 by $0.13. The firm had revenue of $202.30 million during the quarter, compared to the consensus estimate of $203.20 million. Myriad Genetics had a net margin of 7.07% and a return on equity of 10.07%. The company’s revenue was up 13.1% on a year-over-year basis. During the same quarter last year, the company earned $0.26 earnings per share. On average, equities research analysts anticipate that Myriad Genetics, Inc. will post 1.5 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Systematic Financial Management LP Cuts Position in Myriad Genetics, Inc. (MYGN)” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.dailypolitical.com/2018/11/20/systematic-financial-management-lp-cuts-position-in-myriad-genetics-inc-mygn.html.

Myriad Genetics Profile

Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.

See Also: Calculate Your Return on Investment (ROI)

Want to see what other hedge funds are holding MYGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myriad Genetics, Inc. (NASDAQ:MYGN).

Institutional Ownership by Quarter for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.